A consensus redefinition of transfusion-related acute lung injury. by Vlaar, Alexander PJ et al.
UCSF
UC San Francisco Previously Published Works
Title
A consensus redefinition of transfusion-related acute lung injury.
Permalink
https://escholarship.org/uc/item/0ms3d4zw
Journal
Transfusion, 59(7)
ISSN
0041-1132
Authors
Vlaar, Alexander PJ
Toy, Pearl
Fung, Mark
et al.
Publication Date
2019-07-01
DOI
10.1111/trf.15311
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
C O M M I T T E E R E P O R T
A consensus redefinition of transfusion-related acute lung injury
Alexander P.J. Vlaar,1,2 Pearl Toy,3 Mark Fung,5 Mark R. Looney,4 Nicole P. Juffermans,1,2 Juergen Bux,6
Paula Bolton-Maggs,7 Anna L. Peters,8 Christopher C. Silliman,9 Daryl J. Kor,10 and Steve Kleinman11
BACKGROUND: Transfusion-related acute lung injury
(TRALI) is a serious complication of blood transfusion and
is among the leading causes of transfusion-related
morbidity and mortality in most developed countries. In the
past decade, the pathophysiology of this potentially life-
threatening syndrome has been increasingly elucidated,
large cohort studies have identified associated patient
conditions and transfusion risk factors, and preventive
strategies have been successfully implemented. These
new insights provide a rationale for updating the 2004
consensus definition of TRALI.
STUDY DESIGN AND METHODS: An international
expert panel used the Delphi methodology to develop a
redefinition of TRALI by modifying and updating the 2004
definition. Additionally, the panel reviewed issues related
to TRALI nomenclature, patient conditions associated
with acute respiratory distress syndrome (ARDS) and
TRALI, TRALI pathophysiology, and standardization of
reporting of TRALI cases.
RESULTS: In the redefinition, the term “possible TRALI”
has been dropped. The terminology of TRALI Type I
(without an ARDS risk factor) and TRALI Type II (with an
ARDS risk factor or with mild existing ARDS) is proposed.
Cases with an ARDS risk factor that meet ARDS
diagnostic criteria and where respiratory deterioration over
the 12 hours before transfusion implicates the risk factor as
causative should be classified as ARDS. TRALI remains a
clinical diagnosis and does not require detection of cognate
white blood cell antibodies.
CONCLUSIONS: Clinicians should report all cases of
posttransfusion pulmonary edema to the transfusion service
so that further investigation can allow for classification of
such cases as TRALI (Type I or Type II), ARDS,
transfusion-associated circulatory overload (TACO), or
TRALI or TACO cannot distinguish or an alternate
diagnosis.
ABBREVIATIONS: ARDS = acute respiratory distress syndrome;
BNP = brain natriuretic peptide; CCC = Canadian Consensus
Conference; GIFT = granulocyte immunofluorescence test;
ISBT = International Society for Blood Transfusion; LAH = left atrial
hypertension; LPS = lipopolysaccharide; PEEP = positive end-
expiratory pressure; P/F = PaO2/FiO2; pTRALI = possible TRALI;
TACO = transfusion-associated circulatory overload;
TAD = transfusion-associated dyspnea.
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I
n 2004, Canadian Blood Services convened a (Canadian)
Consensus Conference (CCC) on transfusion-related
acute lung injury (TRALI).1 The outcome of the CCC was
to formulate a standardized definition of TRALI to facili-
tate research on its epidemiology, pathophysiology, and risk
mitigation (i.e., prevention) as well as to provide a framework
for decisions about appropriate case investigation and donor
testing. The CCC defined two entities: TRALI and possible
TRALI (pTRALI). The latter category was established for
patients with a clinical syndrome that met the TRALI definition
but who concurrently had a risk factor for the acute respiratory
distress syndrome (ARDS). These two categories were created
to explore whether they represented separate groups from epi-
demiologic and/or pathophysiologic perspectives and, through
ongoing research, to determine whether pTRALI cases were
due to transfusion versus a nontransfusion ARDS risk factor.
Considerable information from prospective and retrospec-
tive research studies and from hemovigilance (HV) systems has
accumulated in the 14 years since the CCC.2 For the most part,
these studies and/or hemovigilance summaries have reported
their data using the CCC definitions, although a careful reading
of the literature reveals that certain aspects of the definitions
were applied differently. For example, studies have not been
uniform in how they distinguished TRALI from pTRALI and,
due to small numbers of cases, some studies have reported
these outcomes in aggregate rather than separately.3
Several groups have synthesized this accumulated infor-
mation and made recommendations for and against changes
in the definitions of TRALI and pTRALI.4–8 Several of the
authors of these publications decided that a substantial contri-
bution could be made if a more stringent and inclusive review
process was undertaken. Another motivation for this effort
was the recognition that pulmonary medicine experts had
redefined acute lung injury (ALI) and ARDS at a 2012 consen-
sus conference in Berlin (referred to as the Berlin definition),
but the transfusion medicine field had yet to incorporate this
information in its consideration of TRALI.9
A panel of experts was convened and agreed that the
current TRALI definition no longer encompassed all current
knowledge on the subject and decided to reconsider the defi-
nition of TRALI including criteria for diagnosis, clinical find-
ings, timing of onset, and relationship to ARDS risk factors. In
addition, the panel broadened out its review to include issues
related to TRALI nomenclature, conditions associated with
ARDS and TRALI, TRALI pathophysiology, differential diag-
nosis (e.g., distinguishing TRALI from transfusion-associated
circulatory overload [TACO]), and standardization of the
reporting of TRALI case data both in research and in
hemovigilance settings. This article reports the results of the
panel’s work and identifies areas for further inquiry.
MATERIALS AND METHODS
The TRALI redefinition and other TRALI-related recommen-
dations proposed in this article resulted from application of
Delphi panel method, a method used to achieve expert consen-
sus.10 It represents a structured process to collect knowledge by
defining a problem, selecting a panel of experts, developing
questions to resolve using open-ended questionnaires, and
performing controlled assessment and feedback until consen-
sus is established.
The TRALI Delphi panel consisted of 10 international
experts. Most were academics and clinicians who had con-
ducted and published TRALI related research or policy articles.
The panel included two hemovigilance experts: one rec-
ommended by AABB and one by the International Society for
Blood Transfusion (ISBT) based on their TRALI expertise. The
panel co-chairs (AV and SK) drafted the first round of ques-
tions (Appendix S1) sent to the panel. Responses were then
collated anonymously by a panel secretary (AP) and summa-
rized and discussed on a conference call. This gave rise to the
co-chairs generating a second round of questions, some of
which reexamined first round questions for which there was
not yet consensus (Appendix S1). In total two Delphi rounds
took place. Several subsequent teleconferences and e-mail
exchanges were held to discuss issues and obtain consensus.
RESULTS
TRALI redefinition and proposed new nomenclature
The 2004 CCC definitions introduced the term pTRALI for
patients who fulfilled the clinical criteria for TRALI in the
presence of an ARDS risk factor. The use of the word “possible”
was intended to indicate that it was unclear whether the
ARDS risk factor or the transfusion was causing the ALI
(Table 1).1 Thus, application of this definition resulted in
cases where an ARDS risk factor was present being excluded
as TRALI cases and also resulted in cases of ARDS being
classified as pTRALI.11
Clinical and preclinical studies have shown that an inflam-
matory “first hit” is almost always present before TRALI
onset,12 and some clinical studies have identified ARDS risk
factors that may also be TRALI risk factors (see below).13–16
Analysis of these data led our panel to recommend dropping
the pTRALI terminology and, instead, using clinical criteria and
clinical judgment to classify such patients as either having
TRALI or having ARDS. This approach is similar to one origi-
nally proposed by the NHLBI Working Group on TRALI.17
Additionally, we propose that TRALI be further subclassified
into two categories: TRALI Type I (without an ARDS risk factor)
and TRALI Type II (with an ARDS risk factor or with existing
mild ARDS; Tables 2 and 3). For a case to be classified as TRALI
Type II, the case must meet three conditions: 1) fulfill the same
clinical criteria as TRALI Type I (see Table 2, TRALI Type I,
Section a); 2) the onset of posttransfusion pulmonary edema
occurred in the presence of an ARDS risk factor or mild ARDS;
and 3) there has been a stable pulmonary status (e.g., based on
PaO2/FiO2 [i.e., P/F] ratio) in the 12 hours before transfusion.
Cases that meet the first two criteria but did not meet the third
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criterion should be classified as ARDS unless the case lacks
documentation that the P/F ratio is less than 300. In this latter
circumstance, the case should be classified as transfusion-
associated dyspnea (TAD).
Harmonization of the new TRALI definition with the
Berlin ARDS definition
The 1994 American European Consensus Criteria (AECC)18
for diagnosing ALI or ARDS was updated by pulmonary med-
icine experts in 2012.19 In this updated definition (i.e., the
Berlin definition), the term ALI was dropped and replaced by
mild ARDS. Nevertheless, because TRALI terminology is
entrenched in transfusion medicine and hemovigilance sys-
tems worldwide, we propose retaining the term TRALI and
not changing it to TR-ARDS.
Our new definition is aligned with most of the Berlin
criteria. First, we slightly altered the 2004 CCC list of ARDS risk
factors to more closely parallel those in the Berlin definition
with some minor deviations (Table 4), based on the premise
that the Berlin list was vetted and approved by numerous
ARDS experts but did not fully consider the transfusion set-
ting. Specifically, consistent with the 2004 CCC, we agree that
multiple (massive) transfusions should not exclude a case as
TRALI Type I; however, if a multiply transfused patient had an
ARDS risk factor, the case would be further evaluated and then
classified as TRALI Type II, ARDS, or TAD (as discussed above
and below). Second, in line with the Berlin definition, we
revised the diagnostic criteria for bilateral pulmonary edema
and left atrial hypertension (LAH) by including use of additional
diagnostic imaging modalities such as chest CT scan or lung
ultrasound (Table 2). Given the declining use of pulmonary
artery catheters, the pulmonary artery wedge pressure criterion
was removed from the LAH criterion. Also, because hydrostatic
pulmonary edema in the form of cardiac failure or fluid over-
load may coexist with ARDS, the new TRALI definition recog-
nizes that even though some degree of LAH may be present, a
case may still be classified as TRALI. This requires a determina-
tion of whether the main driver of respiratory deterioration is
inflammatory lung edema (e.g., TRALI or ARDS) or hydrostatic
TABLE 1. 2004 CCC definition of TRALI and possible TRALI
1. TRALI a. i. Acute onset
ii. Hypoxemia Research setting:
P/F ≤ 300 or SpO2 < 90% on room air
Nonresearch setting:
P/F ≤ 300 or SpO2 < 90% on room air or other
clinical evidence of hypoxemia
iii. Bilateral infiltrates on chest radiograph
iv. No evidence of LAH and/or
central venous pressure <18 mmHg
b. No existing ALI before transfusion
c. During or within 6 hr of transfusion
d. No temporal relationship to an alternative risk factor for ALI
2. Possible TRALI a. As mentioned above
b. In the presence of an alternative risk factor for ALI
TABLE 2. New consensus TRALI definition
TRALI Type I—Patients who have no risk factors for ARDS and meet the following criteria:
a. i. Acute onset
ii. Hypoxemia (P/F ≤ 300* or SpO2 < 90% on room air)
iii. Clear evidence of bilateral pulmonary edema on imaging (e.g., chest radiograph, chest CT, or ultrasound)
iv. No evidence of LAH† or, if LAH is present, it is judged to not be the main contributor to the hypoxemia
b. Onset during or within 6 hr of transfusion‡
c. No temporal relationship to an alternative risk factor for ARDS
TRALI Type II—Patients who have risk factors for ARDS (but who have not been diagnosed with ARDS) or who have existing mild ARDS (P/F of
200-300), but whose respiratory status deteriorates§ and is judged to be due to transfusion based on:
a. Findings as described in categories a and b of TRALI Type I, and
b. Stable respiratory status in the 12 hr before transfusion
* If altitude is higher than 1000 m, the correction factor should be calculated as follows: [(P/F) × (barometric pressure/760)].
† Use objective evaluation when LAH is suspected (imaging, e.g., echocardiography, or invasive measurement using, e.g., pulmonary artery
catheter).
‡ Onset of pulmonary symptoms (e.g., hypoxemia—lower P/F ratio or SpO2) should be within 6 hours of end of transfusion. The additional find-
ings needed to diagnose TRALI (pulmonary edema on a lung imaging study and determination of lack of substantial LAH) would ideally be
available at the same time but could be documented up to 24 hours after TRALI onset.
§ Use P/F ratio deterioration along with other respiratory parameters and clinical judgment to determine progression from mild to moderate or
severe ARDS. See conversion table in Appendix S2 to convert nasal O2 supplementation to FiO2.
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lung edema (e.g., CHF or TACO). When available, objective
criteria such as echocardiography and/or invasive measurement
such as pulmonary artery wedge pressure should be used;
however, clinical judgment may also be required.21 In
some cases, biomarkers (brain natriuretic peptide [BNP]
or NT-proBNP) at onset of pulmonary symptoms may be
useful: when low (BNP < 300 pg/mL or NT-proBNP
< 2000 pg/mL), they can rule out TACO or when high
(NT-proBNP posttransfusion/pretransfusion ratio > 1.5),
they may suggest TACO.22,23 However, since in critically ill
patients and severe TRALI cases these biomarkers are always
elevated due to hypoxic vasoconstriction, NT-proBNP is only
likely to be useful in the general patient population and in cases
with mild pulmonary symptoms.24
We determined that the Berlin criterion of using ventilator
support (e.g., at least 5 cmH2O positive end-expiratory pres-
sure [PEEP] treatment) as a necessary criterion to diagnose
ARDS is not applicable for diagnosing TRALI. The Berlin
PEEP criterion was mainly developed to eliminate the effect
of conditions such as atelectasis on a reduced P/F ratio. The
application of PEEP is mostly performed in an intensive care
setting, which for the general ARDS population is fine. How-
ever, since TRALI may develop on the ward as a mild lung
injury in which only supplemental oxygen is needed, the
PEEP criterion is unnecessarily restrictive.
Posttransfusion time frame for TRALI occurrence
There was unanimous consensus that the time frame in
which TRALI could occur should not change from the origi-
nal definition, that is, within 6 hours after transfusion. This
recommendation is based on the current universal practice in
hemovigilance systems and the lack of robust data supporting
change. In addition, data from the earlier years of the UK
SHOT program where a 24-hour time frame had been used
indicated that there were no additional verified cases when
using this longer time frame.25 The 6-hour time frame refers
to the occurrence of respiratory compromise or hypoxemia.
The additional findings needed to diagnose TRALI (pulmo-
nary edema on lung imaging and determination of lack of sig-
nificant LAH) would ideally be available at the same time but
could be documented up to 24 hours after TRALI onset.26,27
Diagnosis of TRALI Type II
Accumulated evidence indicates that an inflammatory under-
lying condition may serve as first hit in the onset of TRALI.12
Based on preclinical and clinical observations, the presence of
a first hit increases the likelihood of developing TRALI after a
transfusion. Although in experimental settings this mecha-
nism has been confirmed by several groups, the translation to
the clinical setting remains challenging7,28–38 as it is possible
that the underlying condition itself rather than the transfusion
is causative for pulmonary edema. To accommodate this
uncertainty and based on expert consensus and only a low
level of published evidence, the panel recommends that a
patient with an ARDS risk factor who shows no respiratory
deterioration in the 12 hours before transfusion and who then
deteriorates after transfusion be classified as having TRALI
and further subclassified as TRALI Type II. Although changes
in respiratory status (particularly with regard to oxygenation)
TABLE 3. Classification of pulmonary edema not fulfilling TRALI criteria*
• ARDS: Patients who have risk factors for ARDS, and deteriorate not due to transfusion, but as a consequence of the already present ARDS
risk factors.
a. Onset of ARDS within 6 hr after transfusion but respiratory status was deteriorating in the 12 hr before transfusion
b. Existing ARDS of any severity that further deteriorates after transfusion where respiratory status was already deteriorating in the
12 hr before transfusion
• TRALI/TACO cannot be distinguished: Patients in whom TRALI cannot be distinguished from TACO or in whom both conditions occur
simultaneously
a. Clinical findings compatible with TRALI and with TACO and/or lack of data to establish whether or not significant LAH is present
* If pulmonary edema occurs greater than 6 hours after the transfusion, and is clinically suspicious for temporal association with transfusion,
the case should be classified as TAD as is currently done in many hemovigilance systems.
TABLE 4. ARDS risk factors according to the Berlin
definition (with slight modification due to
consideration of the transfusion setting)*
Direct
Pneumonia
Aspiration of gastric contents
Inhalational injury
Pulmonary contusion
Pulmonary vasculitis
Drowning
Indirect
Nonpulmonary sepsis
Major trauma†
Pancreatitis
Severe burns
Noncardiogenic shock*
Drug overdose
* Multiple (massive) transfusion is included in the Berlin definition
of ARDS risk factors; however, we have removed it from this list
because we recommend that ARDS occurring during or within
6 hours after multiple transfusions be classified as TRALI, pro-
vided no other ARDS risk factors (as listed in this table) are pre-
sent. One example of a case scenario of multiple (massive)
transfusion that fits the criteria for TRALI Type I is acute gastroin-
testinal bleeding without trauma or any other ARDS risk factors.
† Major trauma is defined as multiple fractures (two or more major
long bones, an unstable pelvic fracture, or one major long bone
and a major pelvic fracture).20 An alternate definition proposed
by the Panel is an injury severity score of greater than 15.
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are often best determined using the P/F ratio [see Appendix
S2]), it is recommended that the full clinical picture be evalu-
ated when determining the transfusion recipient’s respiratory
status (e.g., markers of oxygenation, respiratory rate, work of
breathing, respiratory support requirements). Many factors
can modify the P/F ratio without meaningfully impacting the
patient’s actual respiratory status. Examples of such circum-
stances may include prone positioning, neuromuscular paral-
ysis, PEEP titration, or inversed-ratio ventilation. Similarly, the
implementation of these respiratory support maneuvers may
signal a decline in respiratory status despite stable P/F ratio
measurements. In these circumstances, clinical judgment
should accompany the use of the P/F ratio in determining the
transfusion recipient’s respiratory status. Therefore, we rec-
ommend that expert panels evaluating reported TRALI cases
should include physicians with understanding of mechanical
ventilation and respiratory medicine. A further proposed
expansion of the TRALI definition is based on the premise that
a progression of mild ARDS to severe ARDS may be due to
transfusion and recognizes that such cases should be classi-
fied as TRALI; that is, in contrast to the 2004 CCC, mild
pretransfusion ALI (i.e., mild ARDS) does not rule out a subse-
quent diagnosis of TRALI.
We recommend that a patient who develops ARDS within
6 hours of transfusion in the presence of respiratory deteriora-
tion in the 12 hours before transfusion be classified as ARDS.
Tabulating these cases separately in hemovigilance systems to
distinguish them from ARDS without transfusion would allow
for future research to ascertain whether transfusion may have
contributed to causation in some of these cases. Potential
hemovigilance system terminology could be: 1) ARDS with
apparent incidental transfusion or 2) ARDS temporally related
to transfusion.
Patient conditions and transfusion risk factors
associated with TRALI
Based on large TRALI cohort studies, conditions associated with
TRALI have been identified. TRALI is thought to involve a
“two-hit” pathophysiology in which the first hit is the underly-
ing condition of the patient (e.g., a proinflammatory condition)
and the “second hit” is the transfusion.12 Human data show
that higher concentrations of interleukin (IL)-8 in the patient’s
pretransfusion plasma is an independent risk factor for
TRALI.39 That is, inflammation from any cause is the first hit in
humans and physiologically results in priming of neutrophils
and/or other effector cells. This may explain why critically ill
and injured patients are especially at risk for TRALI. Based on
preclinical and clinical studies, specific underlying conditions
that result in monocyte, neutrophil, and/or endothelial activa-
tion or priming and which thereby may increase the risk of
ARDS after a blood transfusion have been identified.28,35–37,40–42
The panel decided that evaluating conditions associated
with TRALI required a critical literature appraisal which was
performed by five panel members (PT, SK, DK, ML, and AV).
Identified patient conditions previously associated with TRALI,
pTRALI, and ARDS are summarized in Table 5. The complexity
in diagnosing TRALI in the presence of an ARDS risk factor is
that first or second hits alone, if strong enough, can cause
ARDS. For example, higher doses of first hits such as lipopoly-
saccharide (LPS) in animal models or sepsis in patients can
cause ARDS. Similarly, second hits alone, if strong enough, can
cause ARDS. For example, transfusion of strong (mean fluores-
cence intensity [MFI] > 1500, see below) HLA Class II antibody
can cause TRALI in a healthy subject.49–52 These observations
resulted in the establishment of the TRALI threshold model.53
Although any inflammatory condition probably could
serve as a first hit in TRALI, we limit our discussion below
TABLE 5. Conditions historically associated with
TRALI and ARDS
I. Conditions historically associated with TRALI and pTRALI that
are also major ARDS risk factors in the Berlin definition
(Table 4)*
• Sepsis†
• Noncardiogenic shock‡
• Massive transfusion§
II. Conditions historically associated with TRALI (or both TRALI
and ARDS) but not listed as major ARDS risk factors in the
Berlin definition (Table 4)*
• Cardiac surgery13,43
• Increased pretransfusion plasma IL-839
• Mechanical ventilation with peak airway pressure >30 cm
H2O
39
• Chronic alcohol abuse39
• Current smoker39
• Positive fluid balance39
• Higher APACHE II score14,16
• Increased age13
• End-stage liver disease15
• Postpartum hemorrhage44
• Liver transplantation surgery39,45
• Thrombotic microangiopathy44
• Surgery requiring multiple transfusions46
• Hematologic malignancy16,43,44
NB: The conditions listed in this table are not diagnostic criteria
for TRALI Type I and II.
* Of note, most patient conditions associated with TRALI have
not been consistently found across all studies. The variability of
findings may be explained by differences in study design
including type of patient population, differing case mixes of
TRALI and pTRALI13–16,55 prospective versus retrospective,
and passive versus active reporting.
† Sepsis: For analysis purposes, several studies combined TRALI
and pTRALI cases.14,16,55
‡ Noncardiogenic shock: In one study in which noncardiogenic
shock was shown to be a TRALI risk factor, the definition of
noncardiogenic shock excluded cardiogenic and septic shock
while including hemorrhagic shock, intensive care unit patients
on vasopressors for hypotension associated with sedation, and
a category of “other” shock for shock that could not be classified
into established categories.39
§ Historically, before the 2004 CCC, massive transfusion was
associated with ARDS. This finding is partially explained by its
strong association with TRALI. Studies performed before imple-
mentation of plasma TRALI risk mitigation strategies have
shown that massive transfusion may serve as a second hit for
antibody-mediated TRALI or as a first hit when the transfusions
were given before the 6-hour time frame.16
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to those conditions identified in large clinical cohort studies
of TRALI and pTRALI. Knowledge of these conditions should
alert the clinician to clinical scenarios in which TRALI is
more likely to occur. Table 5 provides a concise summary of
these data but should not be used for TRALI diagnosis;
importantly, criteria for diagnosis are provided in Tables 2–4.
Patient conditions associated with TRALI (first hit)
Animal data show that priming is generally necessary for
the development of TRALI.29,31,34–36,41 Multiple investigators
have shown that proinflammatory endothelial activation is
responsible for the first hit in TRALI39,43 and have used LPS
for pulmonary endothelial activation.30,34,48,53,54 Inflamma-
tion may also be initiated through activation of transfusion-
induced coagulopathy.47 Detailed in vitro experimentation
has determined that LPS induces the synthesis and release
of chemokines (e.g., IL-8, growth-related oncogene-α [GROα],
and epithelial neutrophil activating factor-78 [ENA-78]) from
human pulmonary endothelial cells, and these chemokines
induced polymorphonuclear leukocyte (PMN) priming and
firm adherence, whereas immunoprecipitation of these
chemokines inhibited PMN-mediated endothelial cell
destruction.30 In both antibody- and non–antibody-mediated
TRALI models, the LPS first hit resulted in a higher likelihood
to induce TRALI. In large clinical cohort studies, it has been
shown that the presence of sepsis before transfusion resulted
in an increased risk of developing TRALI.14,16,55
Transfusions can also cause inflammation in the human
lung and thus serve as the first hit.47 As the supernatants of
stored red blood cells (RBCs)35,56 and platelets (PLTs)29,36 are
inflammatory, it is not surprising that transfusion of stored
blood products causes inflammation. It has been shown that
massive transfusion (first hit) in the 48 hours before onset of
pulmonary edema resulted in an increased risk of developing
ARDS after transfusion, after a subsequent transfusion of
additional blood units (second hit).16
Mechanical ventilation causes lung inflammation in
mice40,57 and in humans.58 In patients with ARDS, mortality
was greater when the plateau airway pressure was greater than
30 cm H2O.
59 Thus, it is not surprising that TRALI risk was also
associated with pretransfusion peak airway pressure of more
than 30 cm H2O.
39 Chronic alcohol abuse and current smoking
are other existing patient inflammatory conditions identified as
TRALI risk factors in multivariate analysis after controlling for
transfusion and other patient risk factors.39 Larger positive
fluid balance plays a role as it increases hydrostatic pressure
and thus lowers the threshold for developing pulmonary
edema. Also, it can be hypothesized that once pulmonary vas-
cular permeability is increased during TRALI, higher amounts
of fluids will increase the leakage gradient and worsen pulmo-
nary edema. Indeed, larger positive fluid balance was found to
be a risk factor for TRALI39 and was found to be present in
approximately one-third of ARDS patients.60
Certain clinical conditions and/or scenarios are associ-
ated with multiple TRALI risk factors (e.g., inflammation; mul-
tiple transfusions that may contain white blood cell [WBC]
antibodies; lung injury induced by mechanical ventilation; see
Table 5). Major trauma can present with multiple TRALI risk
factors including shock, lung contusion, and (massive) trans-
fusion, all of which induce inflammation. Cardiac surgery
patients may be exposed to several risk factors: for example,
inflammation, peak airway pressure of more than 30 mm H2O
while on a ventilator, and receipt of many transfusions. In one
study, TRALI was observed postoperatively in 2.4% of cardiac
surgery patients.13 When cardiac surgery parameters were
separated in a multivariate model, time on pump was an inde-
pendent TRALI risk factor, which can be explained by the
neutrophil-priming capacity of the cardiopulmonary bypass
circuit. In another cohort study, cardiac surgery was not a sig-
nificant independent TRALI risk factor (odds ratio, 0.921; 95%
confidence interval, 0.239-3.6; p = 0.91) when added to a mul-
tivariate model that included known TRALI risk factors.39
Hematologic malignancy is another condition with
multiple TRALI risk factors (e.g., inflammation, multiple
transfusions),16,43 although in one study, it remained an
independent risk factor after correction for multiple transfu-
sions.16 Other clinical conditions requiring multiple transfu-
sions and associated with increased TRALI risk include intensive
care unit patients admitted with gastrointestinal bleeding,
abdominal aortic surgery,46,61 postpartum hemorrhage,44 stem
cell transplantation,44 and thrombotic microangiopathy.44
Transfusion risk factors (second hit)
Greater number of transfusions
Patients receiving large numbers of blood units have long
been observed to be at higher risk for ARDS. In a TRALI
cohort study, the number of transfusions of any blood or
blood component within 6 hours before TRALI was found to
be an independent TRALI risk factor; however, multivariate
modeling found that this risk was attributable to two specific
measurements: the total amount of strong cognate HLA Class II
antibody (MFI > 1500, using a microbead-based assay on the
Luminex platform) and the total volume of plasma containing
granulocyte-binding antibody (i.e., granulocyte immunofluores-
cence test [GIFT]-positive plasma).39
High-volume plasma products from female donors
Plasma from female donors that contains WBC antibodies is
an important TRALI risk factor39,62,63 and reports from the
TABLE 6. Transfusion risk factors for TRALI
• Cognate HLA Class II antibody39,42,48,53,71
• Cognate HNA antibody30
• Granulocyte antibody positive by GIFT39
• Cognate anti-HLA Class I that activates cells as shown, for
example, by granulocyte aggregation in vitro71 or at least by a
positive by GIFT result
• Higher volume of female plasma39
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United Kingdom,64 France,44 Germany,65 the Netherlands,66
and the United States67 have documented that a risk mitigation
strategy of providing male-only or male-predominant plasma
reduces TRALI incidence. With regard to female plasma as a
pTRALI risk factor and the effect of plasma risk mitigation on
pTRALI, the panel noted that the data are inconclusive,
with some studies showing an association or a mitigation
effect14,16,55,61,68 and others not.13,14,39,69,70 The explanation for
these discordant findings is not completely clear but could be
due to interstudy differences in the criteria used to classify
cases as pTRALI (including whether or not the 2004 CCC list of
ALI risk factors was applied with or without modification), dif-
ferences in analysis method, or perhaps other factors unique
to particular recipient populations.14,39,44,55,61,68,70
HNA antibodies and cognate HLA Class II antibodies
Historically, TRALI was attributed primarily to human leuko-
cyte antigen (HLA) Class I and human neutrophil antigen
(HNA) antibodies. HLA Class II antibodies associated with
TRALI were first described until 2001 when solid-phase tests
for HLA Class II antibodies became more widely available.42
Since then, cognate HLA Class II antibodies have been docu-
mented to often be the causative second hit.14,71 In contrast,
cognate HLA Class I antibodies were found to have much less
of an association with TRALI,71 except when they cause granu-
locyte aggregation in the granulocyte agglutination test.71
HNA antibodies have been implicated as second hits while
other granulocyte-binding antibodies detected by GIFT or
granulocyte agglutination test, but without a clear specificity
to a known neutrophil antigen, may play a role.71
The cognate antibody strength and the volume of plasma
containing the antibody are contributing factors. Transfusion of
larger volumes of HNA antibody and larger volumes of strong
(e.g., MFI > 1500) cognate HLA Class II antibodies increase the
risk for TRALI, when analyzed by multivariate analysis control-
ling for patient risk factors.39 Plasma-rich products (e.g., fresh-
frozen plasma) were associated with higher risk than RBC units
in an international study conducted before a male-predominant
plasma transfusion strategy was in widespread use.72 Table 6
summarizes these transfusion risk factors.
Other factors potentially impacting on diagnosis
Presence of cognate WBC antibodies
There are currently no biomarkers available to diagnose
TRALI. The panel affirmed that TRALI should remain a clinical
diagnosis and that the presence of cognate WBC antibodies
should not be a criterion for diagnosis since other mecha-
nisms (e.g., proinflammatory mediators accumulating in cel-
lular blood products) may cause TRALI. The panel also noted
that the results of an immunologic case workup of recipient
and donors may take weeks to months; thus, the presence
or absence of antibodies does not help the bedside physi-
cian in diagnosing TRALI. Conversely, the panel recognizes
that the presence of cognate WBC antibodies is important
for understanding pathophysiology and for evaluating risk
mitigation strategies (including eligibility of the WBC antibody–
positive donor for future donations) and therefore recom-
mends that such information be collected and reported by
hemovigilance systems.73
Designating cases as TRALI and TACO cannot be
distinguished
Transfusion-associated circulatory overload and TRALI are
both characterized by respiratory distress due to onset of
pulmonary edema within 6 hours of transfusion. However, the
primary mechanism of the pulmonary edema is different. In
TRALI, the primary physiologic abnormality resulting in pul-
monary edema is an increase in capillary permeability, while
in TACO, edema is believed to result primarily from increased
capillary hydrostatic pressure (nonpermeability edema).
To differentiate between TRALI and TACO it is essential
to know whether there is increased hydrostatic pressure in
the lung capillaries. In the past, the gold standard was the mea-
surement of the pulmonary capillary wedge pressure using a
pulmonary artery catheter. However, pulmonary artery catheter
utilization has become increasingly obsolete in clinical practice
as it did not improve outcome in critically ill patients. For this
reason, the Berlin definition dropped the pulmonary capillary
wedge pressure criterion in excluding circulatory overload;
instead, laboratory assays (e.g., BNP), ultrasound, and clinical
variables such as fluid balance are used to evaluate the role of
circulatory overload in the onset of respiratory distress. The
published ISBT diagnostic criteria for TACO, which have
recently undergone revision and field validation also include
tachycardia and increased blood pressure.74 In addition to
these indirect criteria, our panel suggests that the use of an
objective criterion such as echocardiography to differentiate
between TRALI and TACO would be helpful in cases in which
the clinician has ordered such testing.
Based on experience from research studies that involved
extraction of clinical data for review by an expert panel, there
are cases in which data are insufficient to distinguish whether
the diagnosis should be TRALI, TACO, or both. To accommo-
date such cases that are missing critical clinical data, the panel
has added the classification “TRALI/TACO cannot be distin-
guished” (Table 3). This category can also be used in situa-
tions in which distinguishing between TRALI and TACO is not
possible even though relatively complete data have been pro-
vided or when TRALI and TACO occur concurrently at the
same time in the same patient.
Finally, transfusion-transmitted bacterial infection75 or an
anaphylactic reaction should be considered in the differential
diagnosis of posttransfusion pulmonary edema.76 Table 7
summarizes the features of this classification scheme.
Immunologic workup of involved donors
Donors involved in a TRALI case (either Type I or Type II)
should be screened for the presence of HLA Class I and II
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and HNA antibodies and the transfusion recipient for the
cognate antigen(s); in contrast, our recommendation is that
this is not necessary for cases of ARDS or other categories
in our classification scheme. For further in-depth discus-
sion, we refer the reader to the ISBT consensus paper for
immunologic workup of TRALI cases as well as to the 2004
CCC recommendations.1,77
Improvement in reporting
The panel reached consensus that: 1) clinical services
should report all cases of posttransfusion (within 6 hr) pul-
monary edema to the transfusion service even if ARDS risk
factors were present and the clinician believed the case to
be ARDS and 2) the transfusion service should further
investigate cases by working with the clinician to review rel-
evant data and then to classify the case. Of note, surveys of
clinical case reporting indicated that when some ARDS risk
factors were present (e.g., sepsis), clinicians neglected to
report these cases of posttransfusion pulmonary edema to
the transfusion service.11,38,78 However, since some such
cases could now be classified as TRALI Type II based on
careful evaluation, it is important these cases be reported.
Opinions varied as to how to best: 1) structure a case
reporting form and whether it should be the same for routine
hemovigilance reporting versus clinical research studies and
2) establish the necessary dialogue between clinicians and
transfusion medicine specialists. The appropriate administra-
tive structure to review and classify cases needs to be deter-
mined both at the level of individual hospitals and in
hemovigilance systems. At the hospital level, responsibility
could rest with the transfusion service or with a broader multi-
disciplinary committee (e.g., hemotherapy committee, trans-
fusion committee). In addition to clinical information, the
panel believes that the initial reporting should include the
type of component(s) transfused, their volume, and the inter-
val over which each unit was infused in the 6 hours before
pulmonary edema onset.
Characterization of transfusion reactions reported to
hemovigilance systems includes comparing the case find-
ings to diagnostic criteria (i.e., diagnosing the case), grading
the reaction severity, and assigning an imputability as to
whether the signs and symptoms were related to transfusion
rather than another cause. One reason that imputability is
necessary is because case reporting does not always include
all of the needed clinical and laboratory data to accurately
assess the role of transfusion.
Past use of the term “possible TRALI” created ambiguity
with the inherent confusion related to an interpretation of
what the term “possible” was referring to: was it how well the
signs and symptoms matched the reaction definition (i.e., the
symptoms were related to transfusion but the symptom com-
plex did not clearly meet the definition of TRALI) versus
imputability (i.e., the likelihood of the suspected reaction to
be transfusion related). Most commonly, the term possible
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TRALI referred to imputability; that is, ARDS risk factors were
also present at the time of the suspected transfusion reaction.
The newly proposed nomenclature will eliminate this ambigu-
ity. Although cases can be reported as suspected TRALI or
suspected ARDS, we recommend that cases should be
reported simply and without ambiguity as posttransfusion pul-
monary edema. Transfusion medicine specialists would then
conduct a more extensive investigation and would classify a
case as TRALI (Type I or II), ARDS, TACO, TRALI/TACO can-
not be distinguished, TAD, or place the case into another cate-
gory or would rule out a transfusion reaction completely.
We recognize that this detailed classification system differs
from current hemovigilance practice as it includes a larger
number of categories and also incorporates some of the imput-
ability assessment into those categories. Given that this
approach is new, we recommend that its feasibility be evaluated
by hemovigilance experts, perhaps by prospectively evaluating
the feasibility of achieving accurate classification using the
redefinition compared to using the current TRALI definition.
Currently, for cases classified as TRALI, the detection of
donor WBC antibodies (HLA or HNA) that correspond to
recipient cognate antigens is not always a hemovigilance
system reporting requirement. However, the collection of
such information is important to better identify those TRALI
reactions that have a serologic basis versus those not associ-
ated with WBC antibodies. For research purposes it may
also be valuable to collect additional information about the
WBC antibodies (e.g., detection method and titer) although
the panel recognizes that this may be difficult.
FUTURE RESEARCH DIRECTIONS
Several areas in which future research is needed are:
• To establish how the new definition and/or classifica-
tion scheme can be operationalized in hemovigilance
systems including a consideration of how best to gather
the necessary clinical information.
• To reexamine whether currently reported TRALI risk
factors and predisposing clinical conditions can be veri-
fied and, specifically, to investigate whether transfusion
is a risk factor separately for TRALI Type I or Type II.
This is necessary as the current associations were found
using the previous definitions and need to be reevaluated
using the new classification system. Further, since exis-
ting data were obtained before TRALI risk mitigation for
plasma-associated and PLT-associated TRALI, it is possi-
ble that clinical and transfusion factors that were previ-
ously associated with TRALI may no longer be.
• To evaluate the role of transfusion in the onset of ARDS
in the setting of trauma given the frequent coexistence
of tissue damage and hemorrhagic shock.
• To investigate if posttransfusion progression from mild
to moderate or from moderate to severe ARDS has a
transfusion-related mechanism.
• To further explore TRALI pathophysiologic mechanisms
(from RBCs and PLTs and including non–antibody-
mediated TRALI) with the goal of developing an inter-
vention to lower the risk of TRALI after RBC transfusion.
• To develop TRALI and TACO criteria for the neonatal
and pediatric setting as this proposed definition has
been developed only for adults developing transfusion-
related pulmonary complications.
CONCLUSIONS
Evidence accumulated over the past decade has resulted in
the need to update and modify the 2004 CCC definition of
TRALI. Clinicians should be encouraged to report all cases
of posttransfusion pulmonary edema to the transfusion ser-
vice so that further investigation (either conducted jointly by
the transfusion service and the clinical team or through a
hemovigilance system) can allow for classification of such cases
as TRALI (Type I or Type II), ARDS, TACO, TRALI/TACO, TAD,
or an alternate diagnosis.
We encourage transfusion medicine organizations,
hemovigilance systems, and critical care societies to strongly
consider adopting these definitions. We hope that a consensus
classification scheme can be agreed upon so that standardized
uniform definitions can be applied as rigorously as possible to
generate data that can be compared across research studies
and hemovigilance systems. At a minimum, future TRALI
publications should clearly indicate very specifically what defi-
nition and/or classification scheme is used.
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